Literature DB >> 34907741

Cholesterol and glucose profiles according to different fasting C-peptide levels: a cross-sectional analysis in a healthy cohort from the Czech Republic.

Vladimir Kron1,2,3, Miroslav Verner4,5, Ladislav Pesl6, Pavel Smetana1, Jaromir Kadlec1, Daniel Martinik2.   

Abstract

The relationship between glycaemia and lipoprotein metabolism has not been completely clarified, and slight differences may be found between local authors, trials and evaluated parameters. Therefore this cross-sectional study investigated fasting cholesterol and glucose levels along with the determination of atherogenic index in a cohort of healthy individuals from the Czech Republic in relation to their fasting C-peptide levels. Data were collected between 2009 and 2018 and a total of 3189 individuals were stratified by C-peptide reference range (260-1730 pmol/l) into three groups - below (n = 111), within (n = 2952) and above (n = 126). Total, HDL, LDL cholesterol and atherogenic index were used to compare lipoprotein levels by relevant C-peptide concentrations. Participants using the supplements to affect lipid or glycaemia metabolism were excluded from this study. The evaluation of blood parameters in a fasting state included correlations between C-peptide and cholesterols, differences of variances (F-test) and the comparison of lipoprotein mean values (t-test) between the groups created by the C-peptide reference range. Mean values of total (4.9, 5.1, 5.3 mmol/l), LDL (2.6, 3.1, 3.4 mmol/l) cholesterol and atherogenic index (2.1, 2.8, 3.7) were higher with increasing C-peptide levels, whereas HDL was inversely associated with fasting C-peptide concentration. A positive and negative correlation between atherogenic index (rxy = 0.36) and HDL level (rxy = -0.36) with C-peptide values was found. Differences of HDL, LDL and atherogenic index were, in particular, recorded between the groups below and above the reference range of C-peptide (p ≤ 0.001). Considerable differences (p ≤ 0.001) were also observed for the same lipoprotein characteristics between the groups above and within the C-peptide reference. Generally, the type of cholesterol is crucial for the evaluation of specific changes concerning the C-peptide range. Lipoprotein concentrations differ in relation to C-peptide - not only below and above the physiological range, but also inside and outside of it. Conclusions: Fasting levels of cholesterol, plasma glucose, and atherogenic index were strongly associated with fasting C-peptide levels in healthy individuals. Our data suggest that fasting C-peptide could serve as a biomarker for the early detection of metabolic syndrome and/or insulin resistance prior to the manifestation of type 2 diabetes.

Entities:  

Keywords:  Atherogenic index; C-peptide; Cholesterol; HDL; LDL; Lipoprotein

Mesh:

Substances:

Year:  2021        PMID: 34907741     DOI: 10.32725/jab.2021.023

Source DB:  PubMed          Journal:  J Appl Biomed        ISSN: 1214-021X            Impact factor:   1.797


  20 in total

Review 1.  Pathological consequences of C-peptide deficiency in insulin-dependent diabetes mellitus.

Authors:  Ahmad Ghorbani; Reza Shafiee-Nick
Journal:  World J Diabetes       Date:  2015-02-15

2.  Relationship of glycemic control, exogenous insulin, and C-peptide levels to ischemic heart disease mortality over a 16-year period in people with older-onset diabetes: the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR).

Authors:  Flavio E Hirai; Scot E Moss; Barbara E K Klein; Ronald Klein
Journal:  Diabetes Care       Date:  2007-11-19       Impact factor: 19.112

3.  Metabolic disorders and inflammation are associated with familial combined hyperlipemia.

Authors:  María Díaz-Ruiz; María L Martínez-Triguero; Antonio López-Ruiz; Francis Fernández-de la Cruz; Celia Bañuls; Antonio Hernández-Mijares
Journal:  Clin Chim Acta       Date:  2018-09-07       Impact factor: 3.786

4.  C-peptide and the risk for incident complications and mortality in type 2 diabetic patients: a retrospective cohort study after a 14-year follow-up.

Authors:  S Bo; L Gentile; A Castiglione; V Prandi; S Canil; E Ghigo; G Ciccone
Journal:  Eur J Endocrinol       Date:  2012-05-10       Impact factor: 6.664

Review 5.  The clinical utility of C-peptide measurement in the care of patients with diabetes.

Authors:  A G Jones; A T Hattersley
Journal:  Diabet Med       Date:  2013-07       Impact factor: 4.359

Review 6.  A Practical Review of C-Peptide Testing in Diabetes.

Authors:  Emma Leighton; Christopher Ar Sainsbury; Gregory C Jones
Journal:  Diabetes Ther       Date:  2017-05-08       Impact factor: 2.945

7.  C-Peptide and cardiovascular risk factors among young adults in a southern Brazilian cohort.

Authors:  Romildo Luiz Monteiro Andrade; Denise P Gigante; Isabel Oliveira de Oliveira; Bernardo Lessa Horta
Journal:  BMC Endocr Disord       Date:  2018-11-06       Impact factor: 2.763

8.  Optimal Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) Cut-Offs: A Cross-Sectional Study in the Czech Population.

Authors:  Dagmar Horáková; Ladislav Štěpánek; Vladimír Janout; Jana Janoutová; Dalibor Pastucha; Helena Kollárová; Alena Petráková; Lubomír Štěpánek; Roman Husár; Karel Martiník
Journal:  Medicina (Kaunas)       Date:  2019-05-17       Impact factor: 2.430

9.  Biomarker potential of C-peptide for screening of insulin resistance in diabetic and non-diabetic individuals.

Authors:  Haseeb A Khan; Samia H Sobki; Aishah Ekhzaimy; Isra Khan; Mona A Almusawi
Journal:  Saudi J Biol Sci       Date:  2018-06-01       Impact factor: 4.219

10.  Is C-peptide a predictor of severity of coronary artery disease in metabolic syndrome? An observational study.

Authors:  Bhatia Harnishsingh; Bhat Rama
Journal:  Indian Heart J       Date:  2018-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.